Figure 5

SalA reduces TXNIP overexpression in the liver of HFD-fed rats and PA-treated HepG2 cells.
(A,C) The TXNIP protein levels in the hepatic and cellular lysates were determined by Western blotting (n = 3). (B) Hepatic mRNA levels of TXNIP were analyzed by RT-PCR (n = 4). Results are presented as the mean ± SD, **P < 0.01 vs. the control group; ##P < 0.01 vs. the HFD group or the PA-treated group.